

Carboxylic acid esters of pharmaceutical compounds


The present invention relates to carboxylic acid esters of pharmaceutical compounds, e.g. β -lactam antibiotics, such as cephalosporins.

5


In one aspect the present invention provides a pharmaceutically active compound having a carboxylic acid group $-COOH$ as a part of its chemical structure which $-COOH$ group is in the form of a carboxylic acid ester and which carboxylic acid ester is selected from the group consisting of

- 10 - 1-(2,3-disubstituted 1-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and $(C_{1-22})alkylcarbonyloxy$,
- 1-(1,3-disubstituted 2-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and $(C_{1-22})alkylcarbonyloxy$,
- 1-(9H-fluorene-9-yl- $(C_{1-4})alkyloxycarbonyloxy$)-ethyl carboxylic acid ester,
- 15 - 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl carboxylic acid ester and
- 1-(2-amino- $(C_{1-6})alkoxycarbonyloxy$)-ethyl carboxylic acid ester,
with the proviso that, if the pharmaceutically active compound is a penicillin,
then, 1-(2-amino- $(C_{1-4})alkoxycarbonyloxy$)-ethyl carboxylic acid esters are excluded.

20 A pharmaceutically active compound of the present invention includes β -lactam antibiotics, such as cephalosporins and penicillins, e.g. compounds comprising the basic structural elements of groups of formula




or of formula



25

or of formula

- 2 -



wherein X is a substituted pyrrolidinyl or substituted amino(C₁₋₄)alkyl, e.g. substituted by NH=CH-, and ESTER is selected from the group consisting of

- 1-(2,3-disubstituted 1-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 1-(1,3-disubstituted 2-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 1-(9H-fluorene-9-yl-(C₁₋₄)alkanyloxycarbonyloxy)-ethyl carboxylic acid ester,
- 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl carboxylic acid ester,
- 1-(2-amino(C₁₋₆)alkoxycarbonyloxy)-ethyl carboxylic acid ester,

with the proviso that, if the pharmaceutically active compound is a penicillin, then compounds, wherein ESTER is 1-(2-amino(C₁₋₄)alkoxycarbonyloxy)-ethyl-oxy-carbonyl, are excluded.


15 In another aspect the present invention provides a pharmaceutically active compound of the present invention, which is a pharmaceutically active β-lactam, e.g. of formula CEPH, PENICILLIN or CARBAPENEM, wherein ESTER are as defined above, with the proviso that, if the pharmaceutically active compound is a penicillin, then compounds, wherein ESTER is 1-(2-amino(C₁₋₄)alkoxycarbonyloxy)-ethyl-oxy-carbonyl, are excluded.

20 In another aspect the present invention provides a pharmaceutically active compound of the present invention, which is a cephalosporin, e.g. comprising the basic structural elements as set out in formula CEPH, wherein ESTER are as defined above.

25 In another aspect the present invention provides a pharmaceutically active compound of the present invention, which is a penicillin, e.g. comprising the basic structural elements as set out in formula PENICILLIN and ESTER are as defined above, with the proviso that, if the pharmaceutically active compound is a penicillin, then compounds, wherein ESTER is 1-(2-amino(C₁₋₄)alkoxycarbonyloxy)-ethyl-oxy-carbonyl, are excluded.

In another aspect the present invention provides a pharmaceutically active compound of the present invention, which is a β -lactam, e.g. comprising the basic structural elements as set out in formula CARBAPENEM and ESTER are as defined above,

5 In another aspect the present invention provides a pharmaceutically active compound of the present invention, wherein the $-COOH$ group is in the form of an ester, e.g. a group ESTER, which is of formula



wherein R is selected from the group consisting of

10 - disubstituted 1-propoxy or 2-propoxy substituted with OH or (C_{1-22}) alkylcarbonyloxy,
 - 9H-fluorene-9-yl-(C_{1-4})alkoxy,
 - decahydronaphthoxy and
 - amino(C_{1-6})alkoxy,

with the proviso that, if the pharmaceutically active compound is a penicillin, then

15 compounds, wherein ESTER is 1-(2-amino(C_{1-4})alkoxycarbonyloxy)-ethyl-oxy-carbonyl, are excluded.

In another aspect the present invention provides a pharmaceutically active compound of the present invention, wherein the $-COOH$ group is in the form of an ester, e.g. a group ESTER, selected from the group consisting of

20 - 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl-oxy-carbonyl,
 - 1-(2,3-diacetoxy-1-propoxycarbonyloxy)-ethyl-oxy-carbonyl,
 - 1-(1,3-diacetoxy-2-propoxycarbonyloxy)-ethyl-oxy-carbonyl,
 - 1-(2-octanoyloxy-3-acetoxy-1-propoxycarbonyloxy)-ethyl-oxy-carbonyl,
 25 - 1-(2-acetoxy-3-octanoyloxy-1-propoxycarbonyloxy)-ethyl-oxy-carbonyl,
 - 1-(9H-fluorene-9-yl-methoxycarbonyloxy)-ethyl-oxy-carbonyl,
 - 1-(9H-fluorene-9-yl-ethoxycarbonyloxy)-ethyl-oxy-carbonyl,
 - 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl-oxy-carbonyl and
 - 1-(2-amino-ethoxycarbonyloxy)-ethyl-oxy-carbonyl

30 with the proviso that, if the pharmaceutically active compound is a penicillin, then compounds, wherein ESTER is 1-(2-amino(C_{1-4})alkoxycarbonyloxy)-ethyl-oxy-carbonyl, are excluded.

In another aspect the present invention provides a pharmaceutically active compound of the present invention, wherein the -COOH group is in the form of an ester, e.g. a group ESTER, selected from the group consisting of

- 5 - 1-(2,3-disubstituted 1-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 1-(1,3-disubstituted 2-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 1-(9H-fluorene-9-yl-(C₁₋₄)alkanyloxycarbonyloxy)-ethyl carboxylic acid ester, and
- 10 - 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl carboxylic acid ester.

In another aspect the present invention provides a pharmaceutically active compound of the present invention of formula CEPH selected from the group consisting of

- 15 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(3-ethyl-2-(methylimino)-imidazolidin-1-yl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
- 20 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(carbamimidoyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(1,4,5,6,-tetrahydropyrimidin-2-yl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
- 25 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-{methyl-[N-(4-amino-cyclohexyl)-carbamimidoyl]-hydrazonomethyl}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(2-dimethylamino-4,5-dihydro-imidazol-1-yl-imino)-methyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
- 30 - 3-Carbamoyloxymethyl-7-{2-furan-2-yl-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, and
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(3-

ethyl-2-(methylimino)-imidazol-1-yl-imino)-methyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

In another aspect the present invention provides a pharmaceutically active compound of the

5 present invention selected from the group consisting of

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-diacetoxy-1-propoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(1,3-diacetoxy-2-propoxycarbonyloxy)-ethyl ester,
- 15 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,-octanoyl-3-acetoxy-1-propoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2-acetoxy-3-octanoyl-1-propoxycarbonyloxy)-ethyl ester,
- 20 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2-aminoethoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,
- 25 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(decahydro-naphthalen-2-yl-oxycarbonyloxy)-ethyl ester,
- 30 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2-aminoethoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-

ene-2-carboxylic acid 1-(decahydro-naphthalen-2-yl-oxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester,

5 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-([1-(9H-fluoren-9-yl)-ethoxycarbonyloxy]-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[[3-ethyl-2-(methylimino)-imidazolidin-1-yl]-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester,

10 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[[carbamimidoyl]-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[(1,4,5,6,-

15 tetrahydropyrimidin-2-yl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[methyl-[N-(4-amino-cyclohexyl)-carbamimidoyl]-hydrazonomethyl]-8-oxo-5-thia-1-aza-

20 bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[(2-dimethylamino-4,5-dihydro-imidazol-1-yl-imino)-methyl]-8-oxo-5-thia-1-aza-

bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,

25 - 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[(carbamimidoyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[(1,4,5,6,-


30 tetrahydropyrimidin-2-yl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetyl amino}-3-[(2-dimethylamino-4,5-dihydro-imidazol-1-yl-imino)-methyl]-8-oxo-5-thia-1-aza-

bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,

- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-{[3-ethyl-2-(methylimino)-imidazolidin-1-yl]-hydrazonomethyl}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,
- 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-{methyl-[N-(4-amino-cyclohexyl)-carbamimidoyl]-hydrazonomethyl}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,
- 3-Carbamoyloxymethyl-7-{2-furan-2-yl-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester, and
- 3-Carbamoyloxymethyl-7-{2-furan-2-yl-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-ethyl ester,

In another aspect the present invention provides a pharmaceutically active compound of the present invention, which is a compound of formula




20

wherein

ESTER is as defined above,

R_A is a group of formula



25 R_{A1} is unsubstituted or one- or morefold substituted

- (C₆₋₁₈)aryl, e.g. phenyl,
- (C₆₋₁₈)aryloxy, e.g. phenoxy,
- (C₅₋₆)cycloalkenyl-(C₁₋₄)alkyl,

and

R_{A2} is

- hydroxy, (C_{1-4}) alkyl, formyloxy, methyleneamino, azido,

- (C_{6-18}) aryl, e.g. phenyl,

5 - unsubstituted or substituted amino, e.g. heterocycl-l-amino, (C_{3-8}) cycloalkylcarbonylamino, e.g. wherein cycloalkyl optionally is substituted by oxo, SO_3H or carboxyl;

or

b. $—(CH_2)_n—R_{A3}$

10 wherein R_{A3} is

- $S-R_{A4}$, wherein R_{A4} is heterocycl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. pyridinyl, (C_{1-4}) alkyl or (C_{2-4}) alkenyl, which alkyl or alkenyl is optionally substituted by carboxyl, cyano, amino,

- (C_{1-4}) alkyl, which alkyl is optionally substituted by carboxyl, amino,

15 - heterocycl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. thiophenyl, 1-H-tetrazolyl, isoxazolyl, 1H-pyridin-4-on-1-yl, piperazinyl, which heterocycl is optionally substituted by (C_{1-4}) alkyl, amino, phenyl, oxo, halogen, carboxyl,


- (C_{6-18}) aryl, e.g. phenyl,

20 - (C_{6-18}) aryloxy, e.g. phenoxy,

and

n is 0 to 6, e.g. 0 or 1;

or



25 V is N or CH,

R_{A6} is heterocycl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S,


R_{A5} is

- hydroxy,

30 - (C_{1-4}) alkyl, which alkyl is optionally substituted by carboxyl,

- (C_{1-4}) alkoxy, which alkoxy is optionally substituted by carboxyl, halogen, e.g. fluoro;

or



and

R_B is a hydrogen, hydroxyl, halogen, e.g. chloro, (C_{1-4})alkoxy or a group of formula

5 a. $—(CH_2)_m—R_{B1}$

wherein R_{B1} is

- hydrogen, halogen or hydroxy,
- (C_{1-4})alkoxy,
- (C_{1-4})alkylcarbonyloxy, (C_{2-4})alkenylcarbonyloxy, which alkyl- or alkenylcarbonyloxy is optionally substituted by (C_{6-18})aryl, e.g. phenyl or (C_{1-4})alkoxy,
- (C_{1-4})alkoxycarbonyl,
- aminocarbonyloxy,
- heterocycll having 5 or 6 ring members, and 1 to 4 heteroatoms selected from N, O, S including heterocycll anellated with another ring (system) or bridged heterocycll, or
- 10 - $S-R_{B1'}$, wherein $R_{B1'}$ is heterocycll having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S,
- 15 - $S-R_{B1'}$, wherein $R_{B1'}$ is heterocycll having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S,

and

m is 1 to 4, e.g. 1;


or

20 b. $—C=C—R_{B2}$

wherein R_{B2} is

- hydrogen,
- (C_{1-4})alkyl, optionally substituted by (di(C_{1-4})alkyl)(aminocarbonyl(C_{1-4})alkyl)ammonium with an appropriate anion, e.g. chloride, sulfate, nitrate, tetrafluoroborate or is present as an inner salt,
- 25 - (C_{6-18})aryl, such as phenyl, optionally substituted by nitro, or
- heterocycll having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S;


or



30 wherein R_{B3} is heterocycll having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. a triazolyl;

- 10 -

or



optionally anellated with another ring (system), wherein

X, Y and W independently of each other are C, CH, CH₂ or N, which ring is optionally substituted by aminocarbonyl, amino, hydroxyl(C₁₋₄)alkyl,

5 R is not present or is present and is (C₁₋₄)alkyl, m is 0 or 1 and n is 1 or 2.


"Heterocyclyl" includes heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, which may be wholly or partly saturated, e.g. at least one N, which

10 heterocyclyl is optionally anellated with another ring (system), e.g. wherein substituents are selected from hydroxyl, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, amino(C₁₋₄)alkyl, aminocarbonyl, (C₁₋₄)alkoxyimino, imino(C₁₋₄)oxycarbonyloxy(C₁₋₄)alkyl, imino(C₁₋₄)oxyalkyl or iminohalo-(C₁₋₄)alkyl.

Heterocyclyl preferably is pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl,

15 pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, oxazolyl, thiophenyl, azolyl, thiazolyl, triazolyl, benzothiophenyl, furanyl, and tetrazolyl; and may be unsubstituted or substituted by one or more, especially one or two, substituents selected from the group as indicated above.

20 In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula




EP824535

wherein


ESTER is as defined above,

25 R₂ denotes a group of formula

- 11 -



IIb




IIc


wherein

R_4 denotes hydrogen, (C_{1-8})alkyl, (C_{2-8})alkenyl, (C_{3-6})cycloalkyl, phenyl, (C_{1-12})acyl or heterocyclyl,


5 R_5 denotes hydrogen, (C_{1-8})alkyl, (C_{2-8})alkenyl, (C_{3-6})cycloalkyl, phenyl or a group of formula



IId



IIe



IIf

wherein

R_7 denotes (C_{1-8})alkyl or phenyl,

10 R_8 denotes hydrogen, (C_{3-6})cycloalkyl or (C_{1-8})alkyl,

R_9 denotes hydrogen or (C_{1-8})alkyl,

R_{10} denotes hydrogen, (C_{1-8})alkyl, hydroxyl, amino, phenyl, (C_{2-8})alkenyl, (C_{3-6})cycloalkyl, heterocyclyl, or a group of formula $-\text{N}=\text{CH-Phe}$, wherein Phe denotes phenyl,

15 R_9 and R_{10} together with the nitrogen atom denote heterocyclyl,

Z denotes oxygen, sulphur, or $\text{N}-\text{R}_{13}$, wherein

R_{13} denotes hydrogen, (C_{1-8})alkyl or (C_{3-6})cycloalkyl,

R_{11} denotes hydrogen, (C_{1-8})alkyl, phenyl, (C_{3-6})cycloalkyl or heterocyclyl; or

R_4 and R_5 together with the nitrogen denote heterocyclyl,

20 R_6 denotes heterocyclyl,


W denotes N or CH ,

V denotes CH or NO , and

R_3 denotes hydrogen, (C_{1-8})alkyl, halo(C_{1-4})alkyl, (C_{1-12})acyl or carboxyl.

25 In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula

- 12 -



wherein

ESTER is as defined above,

R_{2s} denotes (C₁₋₆)alkyl, ar(C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₂₋₈)alkinyl,5 R_{3s} denotes hydrogen, (C₁₋₆)alkyl, ar(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₈)alkinyl or (C₃₋₈)cycloalkyl.

In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula









10 wherein


ESTER is as defined above,

W denotes CH or N,

V denotes CH or NO,

R₁ denotes hydrogen, (C₁₋₁₂)acyl, carboxyl, alkyl or haloalkyl,15 R₂ denotes a group of formula

- 13 -




wherein

5 X and Y independently of each other each denote (C₂₋₅)alkylene, or (C₂₋₅)alkenylene wherein one -C=C- double bond is present, or, in case of at least C₄-alkenylene, wherein two -C=C- double bonds are present,
R₄ denotes hydrogen or alkyl,
R₅ denotes hydrogen, alkyl, or aminoiminomethyl,


10 R₆ denotes hydrogen, alkyl, cycloalkyl, amino, hydroxy, alkoxy, heterocyclyl or a group of formula -N=CHR₈, wherein R₈ denotes alkyl, aryl or heterocyclyl, or R₅ and R₆ together with the nitrogen atoms to which they are attached denote heterocyclyl,
R'₆ denotes alkyl,
R₇ denotes hydrogen, or

15 R₆ and R₇ together with the nitrogen atom to which they are attached form heterocyclyl.


In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula




20 wherein ESTER is as defined above and R_{EX} is a group of formula



5 In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula



or of formula



wherein


10 ESTER is as defined above,

W is CH or N,

R₁ is hydroxy, (C₁₋₆)alkoxy, halo(C₁₋₆)alkoxy, hydroxycarbonyl(C₁₋₆)alkoxy or (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkoxy,

R₃ is hydrogen, (C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₃₋₆)cycloalkyl,

15 R₄ is hydrogen or (C₁₋₆)alkyl,



is cyclohexyl or phenyl,

R₅ and R₆ independently of each other are hydrogen; (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₆₋₁₈)arylcarbonyl; (C₁₋₆)alkylcarbonyl; (C₆₋₁₈)aryloxy(C₁₋₄)alkylcarbonyl; (C₁₋₆)alkylcarbonyl(C₆₋₁₈)arylcarbonyl; heterocyclyl(C₁₋₆)alkylcarbonyl, wherein heterocyclyl comprises 5 or 6 ring

5 members and 1 to 4 heteroatoms selected from N, O or S; (C₁₋₆)alkylsulfonyl or (C₆₋₁₈)arylsulfonyl,


X is NH, O, S or N-R₈, wherein R₈ is (C₁₋₆)alkyl or (C₃₋₈)cycloalkyl,

Y is O or S, and

n and m independently of each other are 0 or 1.

10

In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula



wherein ESTER is as defined above.

15

In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a cefacetile, cefaclor, cefadroxil, cefalexin, cefaloglycin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin,

20 cefbuperazone, cefcanel, cefdinir, cefditoren, cefedrolor, cefempidone, cefepime, cefetecol, cefetamet, cefivitril, cefixime, cefluprenam, cefmatilen, cefmenoxime, cefmepidium,

cefmetazole, cefminox, cefoperazone, cefodizime, cefpodoxime, cefonicid, cefoperazone,


ceforanide, cefoselis, cefotaxime, cefotetan, cefotiam, cefoxitin, cefozopran, cefpimizole,

cefluprenam, cefoxazol, cefoxitin, cefpiramide, cefprozil, cefquinome, cefradine, cefpirome,

cefrroxadine, cefsulodin, ceftazidime, cefteram, ceftezole, cefributen, ceftiofur, ceftizoxime,

25 ceftriaxone, cefuroxime, cefuzonam, cephabacin, cephamicin A und B und C, deoxycephamicin B or desacetoxy-cephalosporin C (also as a carbamate), wherein the -COOH group is in the form of a group ESTER, wherein ESTER is as defined above.

In another aspect the present invention provides a pharmaceutically active compound of the present invention which is a compound of formula




PENICILLIN-2

5 wherein

ESTER is as defined above, and

a) R_c is a group of formula



wherein

R_{c1} is (C_{6-18}) aryl, e.g. phenyl, (C_{6-18}) aryloxy, e.g. phenoxy, (C_{4-8}) cyclodialkenyl-

10 heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. thienyl, and

R_{c2} is hydroxyl, (C_{1-4}) alkyl, carboxyl, SO_3H , heterocycloloxy carbonyl, wherein heterocyclyl has 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S, methyleneamino, amino or substituted amino, e.g. amino substituted by

15 heterocyclyl carbonyl, wherein heterocyclyl has 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, amino (C_{1-4}) alkyl carbonyl;

or

b) R_c is heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from

N, O, S, optionally anellated with another ring (system), or (C_{6-18}) aryl, e.g. phenyl,

20 optionally anellated with another ring (system).

"Heterocyclyl" includes heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, which may be wholly or partly saturated, e.g. comprising at least one N, which heterocyclyl is optionally anellated with another ring (system), e.g. optionally

25 substituted heterocyclyl, wherein substituents are selected from hydroxy, (C_{1-4}) alkyl, (C_{2-6}) alkenyl, (C_{1-4}) alkoxy, amino (C_{1-4}) alkyl, carboxy (C_{1-4}) alkyl or aminocarbonyl. Heterocyclyl in the meaning of R_{c2} preferably is thienyl and may be unsubstituted or substituted by one or more, especially one or two, substituents, e.g. substituted by amino.

In another aspect the present invention provides a pharmaceutically active compound of the present invention which is an adicillin, almecillin, amdinocillin, amoxicillin, ampicillin, apalcillin, aspoxicillin, azidocillin, azlocillin, benzylpenicillin, carbenicillin, carindacillin, carfecillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, fenbenicillin, fibracillin,

5 flucloxacillin, formidacillin, fuzlocillin, hetacillin, metampicillin, methicillin, mezlocillin, nafcillin, N-acetylisopenicillin N, oxacillin, penicillin F, penicillin G, penicillin K, penicillin N, penicillin S, penicillin V, penicillin X, pheneticillin, phenoxyethylpenicillin, piperacillin, piroxicillin, propicillin, quinacillin, sulbactam, sulbenicillin, temocillin or ticarcillin, wherein the -COOH group is in the form of a group ESTER, wherein ESTER is as defined above.

10

In another aspect the present invention provides a pharmaceutically active compound of the present invention which is meropenem or imipenem.

15 A pharmaceutically active compound provided by the present invention includes e.g. a compound of formula CEPH, PENICILLIN, CARBAPENEM or PENICILLIN-2.

20 A pharmaceutically active carboxylic acid ester provided by the present invention may be in the form of an physiologically-hydrolysable and -acceptable ester. By physiologically-hydrolysable and -acceptable esters as used herein is meant an ester in which the COO⁻ group is esterified and which is hydrolysable under physiological conditions to yield an acid which is itself physiologically tolerable at dosages to be administered. The term is thus to be understood as defining regular pro-drug forms. An ester moiety may be preferably a group which is easily hydrolysable under physiological conditions. Such esters may be administered preferably orally.

25

30 Compounds provided by the present invention, e.g. compounds of formula CEPH, CEPH_{Pref}, PENICILLIN, PENICILLIN-2, CARBAPENEM, I_{PREF}, I_{EX}, IA, IB, I_{EP824535}, I_{EP973780} and I_{WO9948896} are hereinafter designated as "compound(s) of the present invention". A compound of the present invention includes a compound in any form, e.g. in the form of a salt, in free base form or in the form of a solvate.


In a further aspect the present invention provides a compound of the present invention in the form of a salt, e.g. and/or in the form of a solvate.

Such salts include preferably pharmaceutically acceptable salts, although pharmaceutically unacceptable salts are included, e.g. for preparation / isolation / purification purposes.


The present invention thus includes a compound in free base form or, e.g. where such forms exist, in the form of a salt, for example in the form of an acid addition salt, inner salt,

- 5 quaternary salt, and/or in the form of a solvate, for example in the form of a hydrate. A salt may be a pharmaceutically acceptable salt, such as a metal salt, an amine salt or an acid addition salt. Metal salts include for example sodium, potassium, calcium, barium, zinc, aluminum salts, preferably sodium or potassium salts. Amine salts include salts of a compound of the present invention with an amine, for example trialkylamine, procaine, dibenzylamine and benzylamine salts. Acid addition salts include salts of a compound of formula I with an acid, e.g. hydrogen fumaric acid, fumaric acid, naphthalin-1,5-sulphonic acid, hydrochloric acid, deuteriochloric acid. A free form of a compound of the present invention may be converted into a salt/solvate form and *vice versa*.
- 10
- 15 A compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans isomers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of enantiomers or diastereoisomers and mixtures thereof, e.g. racemates. Substituents at any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. E.g. the configuration of the OR group in a group $-C=N-OR$ may be syn [(Z)] and anti [(E)] and is preferably syn [(Z)]. E.g. cis/trans isomers may be present, in case that an aliphatic double bond is present in a compound of the present invention. Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes a compound of the present invention in any isomeric form and in any isomeric mixture.
- 20
- 25
- 30 The present invention also includes tautomers of a compound of the present invention, where tautomers can exist.
- 35 In another aspect the present invention provides a process for the production of a carboxylic acid ester of the present invention comprising the steps
 - a. reacting a compound of formula R-OH wherein R is as defined above with a compound of formula

- 19 -




to obtain a compound of formula



5


b. reacting a compound of formula V with NaI to obtain a compound of formula



and

c. reacting a compound of formula VI with the -COOH group of a pharmaceutically active compound having a carboxylic acid group -COOH as a part of its chemical structure, and
 10 d. isolating a compound of the present invention obtained from the reaction mixture.


A compound of formula IA or IB may be e.g. obtained by reacting a compound of formula




15 wherein

R1 and W are as defined above, and


R2 is a carboxylic group, optionally in the form of a salt, with a compound of formula



or



wherein



, X, Y, R₃, R₄, R₅, R₆, R₈, n and m are as defined above, producing a carboxylic acid ester as described above and isolating a compound of formula IA or IB obtained from

5 the reaction mixture.

In an intermediate of formula IIA or of formula IIIA or IIIB, functional groups, if present, optionally may be in protected form or in the form of a salt, if a salt-forming group is present. Protecting groups, optionally present, may be removed at an appropriate stage, e.g.

10 according, e.g. analogously, to a method as conventional.

If desired, reactive groups in intermediates (starting materials) of the present invention may be protected with protecting groups, which may be or which are split off under the reaction conditions or after termination of the reaction. A compound of the present invention may be isolated from the reaction mixture as appropriate, e.g. according to a method as

15 conventional.

Other pharmaceutically active compound, e.g. cephalosporins, may be prepared according, e.g. analogously, to the processes as described in WO9635692, WO9843981 or WO9948896 and further esterifying as described herein.

20 A compound of the present invention, e.g. in free form or in the form of a salt/solvate, exhibits pharmacological activity, e.g. beside low toxicity, and are therefore useful as pharmaceuticals. In particular, the active compounds of the invention show antimicrobial, e.g. antibacterial, activity against e.g. gram negative and gram positive bacteria, e.g. gram positive bacteria such as Escherichia, e.g. Escherichia coli; Enterobacter, e.g. Enterobacter cloacae; Enterococcus, e.g. Enterococcus faecalis; Klebsiella, e.g. Klebsiella pneumoniae; Streptococcus, e.g. Streptococcus pneumoniae; Staphylococcus, e.g. Staphylococcus aureus; and Pseudomonas, e.g. Pseudomonas aeruginosa, in vitro in the Agar Dilution Test according to National Committee for Clinical Laboratory Standards (NCCLS) 1993, Document M7-A3 Vol.13, No. 25: "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria

that Grow Aerobically - Third Edition, Approved Standard". The active compounds show a MIC ($\mu\text{g}/\text{ml}$) in the Agar Dilution Test from about <6.4 to about >0.0125. The active compounds of the invention show a surprising overall activity spectrum.

- 5 The compounds of the present invention in the form of a salt exhibit the same order of activity as the active compounds of the present invention in free form; optionally in the form of a solvate.
For pharmaceutical use a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more
- 10 compounds of the present invention.

In another aspect the present invention provides a compound of the present invention for use as a pharmaceutical, preferably as an antimicrobial agent, such as an antibiotic.

- 15 In a further aspect the present invention provides a compound of the present invention for use in the preparation of a medicament for the treatment of microbial diseases, for example of diseases caused by bacteria selected from *Escherichia*, *Enterobacter*, *Enterococcus*, *Klebsiella*, *Streptococcus*, *Staphylococcus* and *Pseudomonas*.
- 20 In a further aspect the present invention provides a method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound of the present invention.

Treatment includes treatment and prophylaxis.

- 25 For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmacokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about
- 30 0.05 to about 5 g (e.g. from about 0,625 mg/kg to about 62,5 mg/kg), for example from about 0.1 to about 2.5 g (e.g. from about 1,25 mg/kg to about 31,25 mg/kg), of an active compound of the invention conveniently administered, for example, in divided doses up to four times a day.

A compound of the present invention may be administered by any conventional route, for

example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intramuscular, subcutaneous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration; e.g. in form of coated or uncoated tablets, capsules, (injectable) solutions, solid solutions, suspensions, dispersions, solid

5 dispersions; e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories, preferably orally. e.g. in form of coated or uncoated tablets, capsules, solid solutions, suspensions, dispersions, solid dispersions, powders.

10 Because of activity against various e.g. bacterial strains, compounds of the present invention are indicated for the treatment of microbial diseases, e.g. bacterial diseases. The compounds of the invention may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally employed with cefuroxim axetil. The compound of the present invention may be administered in 15 pharmaceutically acceptable salt form, e.g. acid addition salt form or base addition salt form or in the corresponding free forms, optionally in solvate form. Such salts exhibit the same order of activity as the free forms.

20 The present invention also provides a pharmaceutical composition comprising a compound of the present invention in association with at least one pharmaceutical excipient, e.g. carrier or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers, e.g. further comprising another pharmaceutically active agent.

25 Such compositions may be manufactured accordingly, e.g. analogously to a method as conventional.

30 Other pharmaceutical agents include e.g. other antibiotics, preferably such which may be administered orally.

Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instruction for co-

administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given.

In a further aspect the present invention provides the use of an ester group selected from

5 the group consisting of

- 1-(2,3-disubstituted 1-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 1-(1,3-disubstituted 2-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 10 - 1-(9H-fluorene-9-yl-(C₁₋₄)alkanyloxycarbonyloxy)-ethyl carboxylic acid ester, and
- 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl carboxylic acid ester
for the improvement of oral resorption of a pharmaceutically active compound.

In a further aspect the present invention provides the use of an ester group selected from

15 the group consisting of

- 1-(2,3-disubstituted 1-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 1-(1,3-disubstituted 2-propoxycarbonyloxy)-ethyl carboxylic acid ester, wherein the substituents are selected from the group consisting of hydroxy and (C₁₋₂₂)alkylcarbonyloxy,
- 20 - 1-(9H-fluorene-9-yl-(C₁₋₄)alkanyloxycarbonyloxy)-ethyl carboxylic acid ester,
- 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl carboxylic acid ester and
- 1-(2-amino(C₁₋₆)alkoxy-carbonyloxy)-ethyl carboxylic acid ester,
for the improvement of oral resorption of a pharmaceutically active compound, with the proviso that, if the pharmaceutically active compound is a penicillin, then 1-(2-amino-
- 25 (C₁₋₄)alkoxycarbonyloxy)-ethyl carboxylic acid esters are excluded .

In another aspect the present invention provides a carboxylic acid ester of a pharmaceutically active compound having a carboxylic acid group -COOH as a part of its chemical structure, which ester is selected from the group consisting of 1-(1,3-disubstituted propoxycarbonyloxy)-ethyl carboxylic acid ester, 1-(2,3-disubstituted propoxycarbonyloxy)-ethyl carboxylic acid ester, 1-(9H-fluorene-9-yl-(C₁₋₄)alkanyloxycarbonyloxy)-ethyl carboxylic acid ester, 1-(decahydro-naphthalene-2-yl-oxycarbonyloxy)-ethyl carboxylic acid ester and 1-(2-amino(C₁₋₆)alkoxycarbonyloxy)-ethyl carboxylic acid ester, with the PROVISO that if the

- 24 -

pharmaceutically active compound is a penicillin, then a 1-(2-amino(C₁₋₄)alkoxycarbonyloxy)-ethyl carboxylic acid ester is excluded.

In the following examples all temperatures are given in degree centigrade and are

5 uncorrected. RT means room temperature. EX. is Example.

EXAMPLES

Example 1:

A) Carbonic acid 1-chloro-ethyl ester 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester

20.3 g of 4-methylmorpholine, 230 mg of 4-dimethylaminopyridine and 26.1 g of chloroformic acid 1-chloro-ethyl ester are added at 4° to 24 g of (2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol in 450 ml of CH_2Cl_2 . The mixture obtained is stirred, a salt precipitated is filtered off and the mixture obtained is subjected to chromatography. Carbonic acid 1-chloro-ethyl ester 2,2-dimethyl-[1,3]dioxolan-4-yl-methyl ester is obtained.

B) Carbonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 1-iodo-ethyl ester

10 40 g of carbonic acid 1-chloro-ethyl ester 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester in 300 ml of acetonitrile are added to 151,2 g of NaI in 1.25 l of acetonitrile. The mixture obtained is stirred, a salt precipitated is filtered off and dissolved in ether. The mixture obtained is subjected to extractive washing and solvent is evaporated from the organic layer obtained. Carbonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 1-iodo-ethyl ester is obtained.

15 **C) 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,2-dimethyl-[1,3]dioxolan-4-yl-methoxycarbonyloxy)-ethyl ester**

38 g of carbonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 1-iodo-ethyl ester in 200 ml of dimethylacetamide are added to 41.5 g of 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt in 840 ml of dimethylacetamide. A reaction mixture formed is stirred, poured into 2 l of an ice- H_2O mixture and the mixture obtained is extracted with ethylacetate. The organic layer obtained is washed with saturated Na_2CO_3 -solution, brine, dried, concentrated and a residue formed is triturated with ether. 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,2-dimethyl-[1,3]dioxolan-4-yl-methoxycarbonyloxy)-ethyl ester is obtained.

¹H-NMR (DMSO- d_6): 1.22 (s, 3H); 1.30 (2xs, 3H); 1.56 (d, 3H, $J=6\text{Hz}$); 3.45 (d, 1H, $J=18\text{Hz}$); 3.64-4.30 (m, 6H); 5.33 (2xd, 1H, $J=5\text{Hz}$); 5.68 (m, 1H); 5.83 (m, 1H), 6.05 (2xdd, 1H,

30 $J=5\text{Hz}$, 8Hz); 6.90/6.97 (2xq, 1H, $J=6\text{Hz}$); 8.20 (s, 1H); 9.62 (d, 1H, $J=6\text{Hz}$); 9.84 (d, 1H, $J=8\text{Hz}$)

D) 7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoromethoxyimino)-acetylamino}-3-

[methyl-(imino-piperazin-1-yl-methyl)-hydrazonomethyl]-8-oxo-5-thia-1-aza-

bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-1-propoxycarbonyloxy)-


ethyl ester

12.2 g of N-amino N-methyl-piperazine-1-carboxamidine, 19.4 ml of 2N HCl and 45 ml of H₂O are added to 24.5 g of 7-[2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino]-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxycarbonyloxy)-ethyl ester in 950 ml of dimethylacetamide.

5 A reaction mixture formed is allowed to stand at ambient temperature and from the mixture obtained, solvent is evaporated. The evaporation residue obtained is triturated with ether and the mixture obtained is cooled. 150 ml of HCl-saturated ether are added, the mixture formed is stirred and ether is decanted. The decantation residue obtained is washed, dried and optionally subjected to chromatography. 7-[2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-(fluoro-methoxyimino)-acetylamino]-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxycarbonyloxy)-ethyl ester is obtained.

10

Analogously to procedures as described in example 1, but using appropriate starting materials, compounds of formula



15

wherein R1 and R2 are as defined in TABLE 1 below are obtained. Purification may be carried out optionally.

TABLE 1









Ex.	R ₁	R ₂	¹ H-NMR (d ₆ -DMSO)
1			1.53 (d, 3H, J=6Hz); 3.21 (bs, 1H); 3.27-3.38 (m, 4H); 3.61 (2xd, 1H, J=18Hz); 3.64-3.74 (m, 7H); 3.99 (m, 1H); 4.18 (m, 1H); 4.31/4.35 (2xd, 1H, J=18Hz); 5.29-5.34 (2xd, 1H, J=5Hz); 5.72 (m, 1H); 5.83 (m, 1H); 5.94-6.01 (2xq, 1H, J=5Hz, 8Hz); 6.84-6.94 (2xq, 1H, J=5Hz); 7.91/7.94 (2xs, 1H); 8.23 (s, 2H); 9.01 (bs, 1H); 9.25 (bs, 1H); 9.62 (bs, 2H); 9.82 (2xd, 1H, J=8Hz)

Ex.	R ₁	R ₂	¹ H-NMR (d ₆ -DMSO)
2			1.56 (d, 3H, J=6Hz); 2.06 (2xs, 6H); 3.26 (bs, 3H); 3.37 (bs, 4H); 3.62-3.65 (m, 1H); 3.73 (m, 4H); 4.13-4.39 (m, 5H); 5.20 (m, 1H); 5.33-5.35 (m, 1H,); 5.72 (bs, 1H); 5.85 (bs, 1H), 5.99 (m, 1H,); 6.89-6.98 (m, 1H,); 8.02 (2xs, 1H); 9.03 (bs, 1H); 9.25 (bs, 1H); 9.67 (bs, 2H,); 9.85 (d, 1H, J=8Hz)
3			1.58 (d, 3H, J=6Hz); 2.03 (2xs, 6H); 3.28 (m, 4H); 3.30 (bs, 3H); 3.63 (d, 1H, J=18Hz); 3.72 (m, 4H); 4.13-4.33 (m, 4H); 4.39 (d, 1H, J=18Hz); 5.06-5.22 (m, 1H); 5.32 (d, 1H, J=5Hz); 5.73 (m, 1H); 5.86 (m, 1H), 6.00 (dd, 1H, J=6Hz, 9Hz); 6.98 (m, 1H,); 8.05 (s, 1H); 8.27 (bs, 2H); 9.04 (bs, 1H); 9.28 (bs, 1H); 9.64 (bs, 2H,); 9.84 (m, 1H)
4			0.87 (t, 3H, J=6Hz); 1.25 (m, 8H); 1.50 (m, 2H); 1.56 (d, 3H, J=6Hz); 2.03 (2xs, 3H); 2.30 (m, 2H); 3.25 (m, 4H); 3.30 (m, 3H); 3.58-3.62 (m, 1H,); 3.72 (m, 4H); 4.16-4.35 (m, 4H); 4.38-4.41 (m, 1H,); 5.05-5.20 (m, 1H); 5.30-5.35 (2xd, 1H, J= 6Hz); 5.73 (m, 1H); 5.83 (m, 1H), 6.00 (m, 1H,); 6.90-6.98 (2xq, 1H, J=6Hz); 7.98-8.03 (2xs, 1H); 8.27 (m, 2H); 9.03 (bs, 1H); 9.30 (bs, 1H); 9.67 (bs, 2H,); 9.87 (m, 1H)
5			0.87 (t, 3H, J=7Hz); 1.25 (m, 8H); 1.52 (m, 2H); 1.57 (d, 3H, J=6Hz); 2.22 (2xs, 3H); 2.30 (t, 2H, J=7Hz); 3.27 (m, 4H); 3.33 (bs, 3H); 3.63 (m, 1H,); 3.73 (m, 4H); 4.12-4.41 (m, 5H); 5.20 (m, 1H); 5.33 (2xd, 1H, J=6Hz); 5.73 (bs, 1H); 5.85 (bs, 1H), 5.97-6.03 (m, 1H,); 6.88-6.99 (m, 1H); 7.98-8.06 (m, 1H); 8.28 (bs, 2H); 9.06 (bs, 1H); 9.30 (bs, 1H); 9.67 (bs, 2H,); 9.85 (t, 1H, J=8Hz)

Ex.	R ₁	R ₂	¹ H-NMR (d ₆ -DMSO)
6			1.56 (d, 3H, J=6Hz); 3.10 (m, 2H); 3.20 (m, 4H); 3.30 (2xs, 3H); 3.60 (m, 1H); 3.72 (m, 4H); 4.32 (m, 3H); 5.32 (2xd, 1H, J=5Hz); 5.70 (bs, 1H); 5.83 (bs, 1H), 5.97 (m, 1H); 6.90-6.98 (2xq, 1H, J=6Hz); 7.96 (2xs, 1H); 8.25 (bs, 2H); 8.30 (bs, 2H); 9.10 (bs, 1H); 9.30 (bs, 1H); 9.70 (bs, 2H); 9.73 (m, 1H)
7			1.25-1.85 (m, 16H); 1.56 (d, 3H, J=6Hz); 3.15 (m, 4H); 3.27 (2xs, 3H); 3.60 (m, 1H); 3.62 (m, 4H); 4.37 (d, 1H, J=17Hz); 4.57 (m, 1H); 5.19/5.36 (2xd, 1H, J=6Hz); 5.73-5.87 (m, 2H); 5.99 (m, 1H,); 6.60-6.98 (2xm, 1H); 7.40/7.72 (2xm, 1H); 8.25 (m, 3H); 9.85-9.92 (m, 1H)
8			1.56 (2xd, 3H, J=6Hz); 3.10-3.90 (m, 8H); 3.20 (m, 2H); 3.53 (m, 1H); 4.33 (m, 2H); 4.63 (m, 1H); 5.31 (2xd, 1H, J=5Hz); 5.70 (m, 1H); 5.82 (m, 1H), 5.93-6.02 (2xdd, 1H, J=5Hz, 8Hz); 6.72-6.97 (2xq, 1H, J=6Hz); 8.25 (m, 2H); 8.60-8.70 (2xs, 1H); 9.75 (bs, 2H); 9.80 (2xd, 1H, J=8Hz)
9			1.20-1.87 (m, 16H); 1.56 (d, 3H, J=6Hz); 3.15-3.47(m, 8H); 3.55 (d, 1H, J=18Hz); 4.75 (m, 1H); 5.30 (2xd, 1H, J=5Hz); 5.72 (m, 1H); 5.83 (m, 1H); 6.02 (2xm, 1H,); 6.85/6.95 (2xm, 1H); 8.52/8.62 (2xs, 1H); 9.70 (m, 1H)
10			1.49 (d, 3H, J=5Hz); 3.21 (bs, 3H); 3.30-3.70 (m, 8H); 3.60 (d, 1H, J=18Hz); 4.30 (m,1H); 4.31 (d, 1H, J=18Hz); 4.60 (m, 2H); 5.30 (2xd, 1H, J=5Hz); 5.69 (m, 1H); 5.83 (m, 1H,); 5.92-6.02 (2xm, 1H); 6.82/6.91 (2xq, 1H, J=5Hz); 7.33 (m, 2H); 7.42 (m, 2H); 7.62 (m, 2H); 7.88 (m, 2H); 7.93 (s, 1H); 8.22 (bs, 1H); 8.98 (bs, 1H); 9.22 (bs, 1H); 9.63 (bs, 1H); 9.83 (2xd, 1H, J=8Hz)

Ex.	R ₁	R ₂	¹ H-NMR (d ₆ -DMSO)
11			0.72-0.84 (3xd, 3H, J=6Hz); 1.45-1.63 (3xd, 3H, J=6Hz); 3.30-3.70 (m, 8H); 3.33 (4xs, 3H); 3.62 (d, 1H, J=18Hz); 4.33 (d, 1H, J=18Hz); 4.43 (m, 1H); 5.20-5.99 (m, 5H); 6.65-7.00 (3xq, 1H, J=6Hz); 7.30-8.30 (m, 9H); 9.03-9.30 (m, 3H); 9.83-9.93 (m, 2H)
12			1.20 (2xt, 3H, J=7Hz); 1.51 (d, 3H, J=5Hz); 3.19 (s, 3H); 3.53-3.83 (m, 7H); 4.29-4.40 (m, 2H); 4.53-4.68 (m, 2H); 5.33 (2xd, 1H, J=5Hz); 5.72 (m, 1H); 5.83 (m, 1H); 5.93/6.01 (2xdd, 1H, J=5Hz, 8Hz); 6.83/6.91 (2xq, 1H, J=5Hz); 7.31-7.39 (m, 2H); 7.40-7.46 (m, 2H); 7.62-7.68 (m, 3H); 7.88-7.92 (m, 2H); 8.23 (bs, 1H); 8.62 (bs, 1H); 9.85 (2xd, 1H, J=8Hz)
13			1.50 (d, 3H, J=6Hz); 3.55 (d, 1H, J=18Hz); 4.33 (t, 1H, J=6Hz); 4.57 (d, 1H, J=18Hz); 4.64 (m, 2H); 5.31 (2xd, 1H, J=5Hz); 5.71 (m, 1H); 5.82 (m, 1H,); 5.93/6.02 (2xdd, 1H, J=5Hz, 8Hz); 6.71/6.91 (2xq, 1H, J=6Hz); 7.31-7.48 (m, 4H); 7.65 (m, 2H); 7.80 (bs, 2H); 7.95 (m, 2H); 8.25-8.30 (2xs, 1H); 8.27 (bs, 2H); 9.85 (2xd, 1H, J=8Hz); 12.10 (bs, 1H)
14			1.52 (d, 3H, J=6Hz); 1.90 (m, 2H); 3.35 (m, 4H); 3.55 (d, 1H, J=18Hz); 4.32 (t, 1H, J=6Hz); 4.59 (2xd, 1H, J=18Hz); 4.62 (m, 2H); 5.31 (2xd, 1H, J=5Hz); 5.71 (m, 1H); 5.83 (m, 1H,); 5.91/6.01 (2xdd, 1H, J=5Hz, 8Hz); 6.80/6.90 (2xq, 1H, J=6Hz); 7.32-7.43 (m, 4H); 7.63 (m, 2H); 7.90 (m, 2H); 8.35 (s, 1H); 8.45 (s, 1H); 9.85 (2xd, 1H, J=8Hz)

Ex.	R ₁	R ₂	¹ H-NMR (d ₆ -DMSO)
15			1.50-1.59 (m, 4H); 1.52 (d, 3H, J=6Hz); 1.92-2.03 (m, 4H); 2.94 (m, 1H); 3.27 (2xs, 3H); 3.57 (d, 1H, J=18Hz); 3.63 (m, 1H); 4.32 (m, 1H); 4.53-4.68 (m, 3H); 5.32 (2xd, 1H, J=5Hz); 5.72 (m, 1H); 5.83 (m, 1H,); 5.95/6.01 (2xdd, 1H, J=5Hz, 8Hz); 6.84/6.91 (2xq, 1H, J=6Hz); 7.31-7.38 (m, 2H); 7.42-7.47 (m, 2H); 7.63 (m, 2H); 7.89 (m, 2H); 7.91 (2xs, 1H); 8.05 (bs, 1H); 8.20 (bs, 2H); 8.27 (s, 2H); 8.48 (bs, 1H); 9.85 (2xd, 1H, J=8Hz)
16			1.51 (2xd, 3H, J=6Hz); 3.23 (bs, 6H); 3.59 (m, 2H); 3.68 (m, 1H,); 3.88 (m, 2H); 4.05 (d, 1H, J=18Hz); 4.34 (m, 1H); 4.62 (m, 2H); 5.32 (2xd, 1H, J=5Hz); 5.73 (m, 1H); 5.85 (m, 12H); 5.96/6.02 (2xdd, 1H, J=5Hz, 8Hz); 6.84/6.92 (2xq, 1H, J=6Hz); 7.37 (m, 2H); 7.42 (m, 2H); 7.65 (m, 2H); 7.90 (m, 2H); 8.24 (bs, 1H); 9.30 (bs, 1H); 9.87 (2xd, 1H, J=8Hz)
17			1.56 (d, 3H, J=6Hz); 3.38 (m, 1H); 3.57 (d, 1H, J=18Hz); 3.68 (m, 2H); 3.99 (ABX-system, 1H, J _{AB} =10Hz, J _{AX} =6Hz); 4.22 (ABX-system, 1H, J _{AB} =10Hz, J _{BX} =5Hz); 4.55 (d, 1H, J=18Hz); 5.31 (2xd, 1H, J=5Hz); 5.73 (m, 1H); 5.83 (m, 1H,); 5.97 (dd, 1H, J=5Hz, 8Hz); 6.95 (q, 1H, J=5Hz); 8.21 (s, 2H); 8.30 (s, 1H); 9.82 (d, 1H, J=8Hz); 12.05 (s, 1H)
18			1.56 (2xd, 3H, J=6Hz); 1.90 (m, 2H); 3.29-3.39 (m, 5H); 3.55 (d, 1H, J=18Hz); 3.69 (m, 2H); 4.00 (m, 1H); 4.20 (m, 1H); 4.57 (2xd, 1H, J=18Hz); 4.75 (m, 1H); 5.08 (m, 1H); 5.33 (2xd, 1H, J=5Hz); 5.71 (m, 1H); 5.85 (m, 1H,); 5.95/6.02 (2xdd, 1H, J=5Hz, 8Hz); 6.85/6.92 (2xq, 1H, J=6Hz); 8.25 (s, 1H); 8.42 (s, 1H); 9.85 (2xd, 1H, J=8Hz); 12.06 (bs, 1H)

Ex.	R ₁	R ₂	¹ H-NMR (d ₆ -DMSO)
19			1.57 (2xd, 3H, J=6Hz); 3.20 (2xs, 3H); 3.28-3.40 (m, 7H); 3.66 (m, 1H,); 3.72 (m, 2H); 3.93 (m, 1H); 4.02-4.08 (m, 2H); 4.20 (m, 1H); 5.31 (2xd, 1H, J=5Hz); 5.70-5.89 (m, 2H); 5.95/6.03 (m, 1H); 6.81/6.98 (m, 1H); 7.73 (m, 1H); 8.12-8.22 (m, 4H); 9.82 (2xd, 1H, J=8Hz)
20			1.50 (2xd, 3H, J=6Hz); 3.20-3.80 (m, 12H); 3.93 (m, 1H); 4.13 (m, 1H); 4.57/4.62 (2xd, 1H, J=18Hz); 5.23-5.34 (2xd, 1H, J=5Hz); 5.66 (m, 1H); 5.80 (m, 1H,); 5.90-5.98 (2xq, 1H, J=5Hz, 8Hz); 6.78/6.84 (2xq, 1H, J=5Hz); 8.20 (s, 2H); 8.48/8.59 (2xs, 1H); 8.50 (bs, 1H); 9.58 (bs, 2H); 9.78 (2xd, 1H, J=8Hz); 12.20/12.31 (2xbs, 1H)
21			1.21 (2xt, 3H, J=7Hz); 1.56 (2xd, 3H, J=7Hz); 3.18 (bs, 3H); 3.30-3.42 (m, 2H); 3.57-3.71 (m, 4H); 3.80-3.88 (m, 4H); 3.94 (m, 1H); 3.98-4.07 (m, 1H); 4.17-4.22 (m, 1H); 4.76 (m, 1H); 5.07 (t, 1H, J=5Hz); 5.36 (2xd, 1H, J=5Hz); 5.74 (m, 1H); 5.86 (m, 1H,); 6.01 (m, 1H); 6.88/6.96 (2xq, 1H, J=5Hz); 7.71 (2xs, 1H); 8.25 (bs, 2H); 8.58 (bs, 1H); 9.85 (2xd, 1H, J=8Hz)
22			1.50-1.59 (m, 4H); 1.52 (d, 3H, J=6Hz); 1.92-2.03 (m, 4H); 2.92 (m, 1H); 3.25 (m, 1H); 3.27 (2xs, 3H); 3.50 (m, 1H); 3.57 (d, 1H, J=18Hz); 3.63 (m, 2H); 3.96 (m, 1H); 4.21 (m, 1H); 4.62 (d, 1H, J=18Hz); 5.27 (2xd, 1H, J=5Hz); 5.72 (m, 1H); 5.83 (m, 1H,); 5.95/6.01 (2xdd, 1H, J=5Hz, 8Hz); 6.84/6.91 (2xq, 1H, J=6Hz); 7.91 (s, 1H); 8.05 (bs, 1H); 8.20 (bs, 2H); 8.27 (s, 2H); 8.48 (bs, 1H); 9.85 (2xd, 1H, J=8Hz)

Example 23:

3-Carbamoyloxymethyl-7-{2-furan-2-yl-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester

5 38 g of carbonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 1-iodo-ethyl ester in 200 ml of dimethylacetamide are added to 41.5 g of cefuroxim in the form of a sodium salt in 840 ml of dimethylacetamide. The mixture obtained is stirred, poured into 2 l of an ice-H₂O mixture and the mixture obtained is extracted with ethyl acetate. The organic layer obtained is washed with saturated Na₂CO₃-solution, brine, dried, concentrated and the concentration 10 residue obtained triturated with ether. 3-Carbamoyloxymethyl-7-{2-furan-2-yl-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(9H-fluoren-9-yl-methoxycarbonyloxy)-ethyl ester is obtained.


15 ¹H-NMR (DMSO-d₆): 1.48 (d, 3H, J=6Hz); 3.55 (d, 1H, J=18Hz); 3.64 (2xd, 1H, J=18Hz); 3.89 (2xs, 3H); 4.31-4.38 (m, 1H); 4.49-4.86 (m, 4H); 5.22 (2xd, 1H, J=5Hz); 5.58-5.89 (m, 1H); 6.60-6.73 (m, 2H); 6.78/6.89 (2xq, 1H, J=6Hz); 7.32-7.38 (m, 2H); 7.42-7.46 (m, 2H); 7.62-7.68 (m, 2H); 7.83 (m, 1H); 7.92 (m, 2H); 9.79 (2xd, 1H, J=8Hz)

Analogously to example 23 but using the appropriate starting materials the following compound is prepared.

Example 24:

3-Carbamoyloxymethyl-7-{2-furan-2-yl-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(2,3-dihydroxy-propoxycarbonyloxy)-ethyl ester

25 ¹H-NMR (DMSO-d₆): 1.50 (d, 3H, J=6Hz); 3.30 (m, 2H); 3.49/ 3.62 (2xd, 1H, J=18Hz); 3.63 (m, 1H); 4.00 (s, 3H); 4.03 (m, 1H); 4.18 (m, 1H); 4.75/4.80 (m, 1H); 5.18-5.24 (2xd, 1H, J=5Hz); 5.80-5.87 (m, 1H); 6.67 (m, 1H); 6.78/6.87 (2xq, 1H, J=6Hz); 7.22 (d, 1H, J=3.5Hz); 7.83 (m, 1H); 9.57 (2xd, 1H, J=8Hz)

INTERMEDIATES**30 Intermediates of formulae****SCHEME 1**

wherein R_2 is as described in TABLE 1 above, are obtained analogously as described in Example 1, but using appropriate starting materials. The $^1\text{H-NMR}$ data of such intermediates is set out in TABLE 2 below.

TABLE 2

Ex`	Chloride (1) $^1\text{H-NMR}$ (CDCl_3)	Iodide (2) $^1\text{H-NMR}$ (CDCl_3)
1`	1.36 (s, 3H); 1.43 (2xs, 3H); 1.83 (d, 3H, $J=6\text{Hz}$); 3.79 (m, 1H); 4.09 (m, 1H); 4.23 (m, 2H); 4.34 (m, 1H); 6.42 (q, 1H, $J=6\text{Hz}$)	$^1\text{H-NMR}$ (CDCl_3): 1.36 (s, 3H); 1.44 (2xs, 3H); 2.25 (2xd, 3H, $J=6\text{Hz}$); 3.78 (m, 1H); 4.09 (m, 1H); 4.22 (m, 2H); 4.33 (m, 1H); 6.75 (m, 1H,)
2`	1.86 (d, 3H, $J=6\text{Hz}$); 2.11 (s, 3H); 2.20 (s, 3H); 4.20 (m, 1H); 4.34 (m, 2H); 4.44 (m, 1H); 5.28 (m, 1H); 6.43 (2xq, 1H, $J=6\text{Hz}$)	2.08 (s, 3H); 2.12 (s, 3H); 2.25 (d, 3H, $J=6\text{Hz}$); 4.18 (m, 1H); 4.30 (m, 2H); 4.42 (m, 1H); 5.24 (m, 1H); 6.74 (2xq, 1H, $J=6\text{Hz}$)
3`	1.84/1.86 (2xd, 3H, $J=6\text{Hz}$); 2.08-2.10 (4xs, 6H); 4.17-4.40 (m, 2H); 5.14-5.28 (m, 1H); 6.41-6.42 (2xq, 1H, $J=6\text{Hz}$)	2.10 (2xs, 3H); 2.27 (d, 3H, $J=6\text{Hz}$); 4.18 (m, 2H); 4.35 (m, 2H); 5.18-5.28 (m, 1H); 6.74 (2xq, 1H, $J=6\text{Hz}$)
4`	0.90 (t, 3H, $J=6\text{Hz}$); 1.30 (m, 8H); 1.63 (m, 2H); 1.87 (d, 3H, $J=6\text{Hz}$); 2.10 (s, 3H); 2.34 (t, 2H, $J=7\text{Hz}$); 4.20 (m, 2H); 4.38 (m, 2H); 5.20 (m, 1H); 6.44 (q, 1H, $J=6\text{Hz}$)	0.90 (t, 3H, $J=6\text{Hz}$); 1.32 (m, 8H); 1.64 (m, 2H); 2.10 (s, 3H); 2.28 (d, 3H, $J=6\text{Hz}$); 2.36 (m, 2H); 4.20 (m, 2H); 4.38 (m, 2H); 5.20 (m, 1H); 6.78 (q, 1H, $J=6\text{Hz}$)
5`	0.87 (t, 3H, $J=6\text{Hz}$); 1.28 (m, 8H); 1.62 (m, 2H); 1.84 (d, 3H, $J=6\text{Hz}$); 2.10 (s, 3H); 2.32 (m, 2H); 4.30 (m, 2H); 4.42 (m, 2H); 5.23 (m, 1H); 6.40 (q, 1H, $J=6\text{Hz}$)	0.87 (t, 3H, $J=6\text{Hz}$); 1.28 (m, 8H); 1.62 (m, 2H); 2.10 (s, 3H); 2.24 (d, 3H, $J=6\text{Hz}$); 2.32 (m, 2H); 4.18 (m, 2H); 4.30 (m, 2H); 5.23 (m, 1H); 6.74 (q, 1H, $J=6\text{Hz}$)
6`	1.44 (s, 9H); 1.83 (d, 3H, $J=6\text{Hz}$); 3.44 (m, 2H); 4.27 (t, 2H, $J=5\text{Hz}$); 6.42 (q, 1H, $J=6\text{Hz}$)	1.44 (s, 9H); 2.24 (d, 3H, $J=6\text{Hz}$); 3.44 (m, 2H); 4.27 (t, 2H, $J=5\text{Hz}$); 6.76 (q, 1H, $J=6\text{Hz}$)
7`	0.90-1.97 (m, 16H); 1.82 (d, 3H, $J=6\text{Hz}$); 4.60 (m, 1H); 6.42 (q, 1H, $J=6\text{Hz}$)	0.90-1.97 (m, 16H); 2.27 (d, 3H, $J=6\text{Hz}$); 4.64 (m, 1H); 6.79 (q, 1H, $J=6\text{Hz}$)
8`	see ex. 6	see ex. 6
9`	see ex. 7	see ex. 7
10`	1.87 (d, 3H, $J=6\text{Hz}$); 4.28 (t, 1H, $J=7\text{Hz}$); 4.42 (dd, 1H, $J=7\text{Hz}, 10\text{Hz}$); 4.52 (dd, 1H, $J=7\text{Hz}, 10\text{Hz}$); 6.46 (q, 1H, $J=6\text{Hz}$); 7.32 (m, 2H); 7.42 (m, 2H); 7.61 (m, 2H); 7.77 (m, 2H)	2.28 (d, 3H, $J=6\text{Hz}$); 4.28 (t, 1H, $J=7\text{Hz}$); 4.40 (dd, 1H, $J=7\text{Hz}, 10\text{Hz}$); 4.53 (dd, 1H, $J=7\text{Hz}, 10\text{Hz}$); 6.70 (q, 1H, $J=6\text{Hz}$); 7.32 (m, 2H); 7.42 (m, 2H); 7.61 (m, 2H); 7.78 (m, 2H)
11`	0.78/0.81 (sxd, 3H, $J=6\text{Hz}$); 1.93/1.94 (2xd, 3H, $J=6\text{Hz}$); 4.39/4.43 (sxd, 1H, $J=4\text{Hz}$); 5.57 (m, 1H); 6.55/6.56 (2xq, 1H, $J=6\text{Hz}$); 7.34 (m, 2H); 7.42 (m, 2H); 7.57 (m, 1H); 7.72 (m, 1H); 7.79 (m, 2H)	0.76/0.89 (sxd, 3H, $J=6\text{Hz}$); 2.21/2.23 (2xd, 3H, $J=6\text{Hz}$); 4.379/4.40 (2xd, 1H, $J=4\text{Hz}$); 5.56 (m, 1H); 6.86/6.88 (2xq, 1H, $J=6\text{Hz}$); 7.30 (m, 2H); 7.40 (m, 2H); 7.52 (m, 1H); 7.70 (m, 1H); 7.73 (m, 2H)

For intermediates of EX12` to example 24` see Examples 1a, 1b and Example 10.

The intermediate numbering indicated with "X" corresponds to the Example number "X" in TABLE 1.

5

3-{{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazone] methyl}-7-{{[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino}-3-cephem-4-carboxylic acid

a) Benzylidene derivative of 3-amino-1-(trans-4-aminocyclohex-1-enyl)-2-propanone

10 35 g of the benzylidene derivative of S-methyl-2-methyl-isothiosemicarbazide in the form of a hydrochloride and 32.79 g of trans-1,4-diaminocyclohexane in 300 ml of MeOH are refluxed. The mixture obtained is stirred at RT, a precipitate formed is filtered off and solvent is evaporated. The evaporation residue obtained is treated with 217.5 ml of 2M HCl, a precipitate formed is filtered off, washed and dried. The product is collected.

15 brought to about 150 ml, a precipitate is formed is filtered off, washed and dried. The dried, combined precipitates are recrystallized from H_2O and the benzylidene derivative of 3-amino-1-(trans-4-aminocyclo hexyl)-3-methyl-guanidine in the form of a monohydrochloride is obtained.

b) 3-Amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine

20 From a mixture of 24.74 g of benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a monohydrochloride in 79.9 ml of 2M HCl, benzaldehyde is distilled off and solvent from the remaining mixture is evaporated. 3-Amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride is obtained.

c) 3-{(E)[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazone}l methyl-7-{[(5-amino-[1,2,4]thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino}-3-cephem-4-carboxylic acid

2.78 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto(2,1-b)furo(3,4-d)(1,3)-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino) acetic acid amide are added to a mixture of 2 g of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride in 3.4 ml of 2M HCl and 6.1 ml of DMA and the suspension obtained is stirred at RT. The mixture obtained is poured into CH₃CN under stirring. A precipitate formed is filtrated off, washed and dried. 3-{(E)[[1-trans-(4-Aminocyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7-{{(5-amino-1,2,4-thiadiazol-3-yl)-

(Z)-(fluoromethoxyimino)-acetyl] amino}-cephem-4-carboxylic acid in the form of a trihydrochloride is obtained.

d) 3-[(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl]-7-[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid

5 10 g of crude 3-[(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl]-7-[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino}-3-cephem-4-carboxylic acid in the form of a trihydrochloride are dissolved in 42 ml of H₂O and subjected to chromatography (LiChroprep® RP-18, Merck, grain size 40-63μm). Fractions 10 containing the desired product in the form of a monohydrochloride are combined and optionally lyophilised. 3-[(E)[[1-Trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl]-7-[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid in the form of a hydrochloride is obtained.
15 ¹H-NMR: 1.30–1.70, m, 4H, CCH₂; 1.80–2.10, m, 4H, CCH₂; 2.88–3.10, m, 1H, NCH; 3.32, s, 3H, NCH₃; 3.42 – 3.70, m, 2H, 1H from SCH₂ and 1H from NCH; 4.25, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.28, d, J=5 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH₂F; 5.75, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.10, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH.